

17 November 2006

To all Pharmaceutical Suppliers, Hospital Pharmacists, Medical Groups and Interested Parties

Consultation on a proposal relating to carvedilol, cilazapril and cilazapril with hydrochlorothiazide

PHARMAC has entered into a provisional agreement with Roche Products (New Zealand) Limited in relation to the pharmaceuticals carvedilol (Dilatrend), cilazapril (Inhibace), and cilazapril with hydrochlorothiazide (Inhibace Plus). Details of the proposals are as below:

- The following pharmaceuticals would continue to be listed in Section B and Part II of Section H of the Pharmaceutical Schedule at the current prices and subsidies:

Chemical	Presentation	Strength	Brand	Price and Subsidy	Pack Size
Carvedilol	Tablet	6.25 mg	Dilatrend	\$21.00	30
Carvedilol	Tablet	12.5 mg	Dilatrend	\$27.00	30
Carvedilol	Tablet	25 mg	Dilatrend	\$33.75	30
Cilazapril	Tablet	0.5 mg	Inhibace	\$2.20	30
Cilazapril	Tablet	2.5 mg	Inhibace	\$4.39	30
Cilazapril	Tablet	5 mg	Inhibace	\$6.44	30
Cilazapril with hydrochlorothiazide	Tablet	5 mg with 12.5 mg	Inhibace Plus	\$6.30	28

Prices and subsidies are ex-manufacturer, ex-GST.

- The Special Authority restriction that currently applies to carvedilol would be removed.
- Dilatrend would be subject to a confidential rebate.
- Dilatrend would have subsidy protection in Section B of the Pharmaceutical Schedule until 31 January 2011.
- Inhibace and Inhibace Plus would have subsidy protection in Section B of the Pharmaceutical Schedule until 30 June 2010.

It is anticipated that the proposed changes, if approved by PHARMAC's Board, would take effect from 1 February 2007. If you wish to make comments for the PHARMAC Board to consider when making its decision on whether to accept this proposal, please forward them to Stephen Woodruffe at PHARMAC by 5:00 pm, 1 December 2006.

Yours sincerely,



Stephen Woodruffe
Therapeutic Group Manager